Mucosal leishmaniasis: the experience of a brazilian referral center

Página do item simplificado
dc.creatorMariana Junqueira Pedras
dc.creatorJanaína de Pina Carvalho
dc.creatorRosiana Estéfane da Silva
dc.creatorMaria Camilo Ribeiro de Senna
dc.creatorDario Brock Ramalho
dc.creatorAna Rabello
dc.creatorGlaucia Fernandes Cota
dc.creatorHugo Silva Assis Moreira[
dc.creatorLorena Zaine Matos Martinho
dc.date.accessioned2024-11-28T20:56:32Z
dc.date.accessioned2025-09-08T23:58:25Z
dc.date.available2024-11-28T20:56:32Z
dc.date.issued2018
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.format.mimetypepdf
dc.identifier.doi10.1590/0037-8682-0478-2017
dc.identifier.issn1678-9849
dc.identifier.urihttps://hdl.handle.net/1843/78355
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofRevista da Sociedade Brasileira de Medicina Tropical
dc.rightsAcesso Aberto
dc.subjectLeishmaniose
dc.subjectTerapia
dc.subjectAntimoniato de Meglumina
dc.subjectAnfotericina B
dc.subjectAzóis
dc.titleMucosal leishmaniasis: the experience of a brazilian referral center
dc.typeArtigo de periódico
local.citation.epage323
local.citation.issue3
local.citation.spage318
local.citation.volume51
local.description.resumoINTRODUCTION: Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS: This study was based on a review of clinical records of 35 patients (24 men and 11 women) treated between 2009 and 2015. RESULTS: The median age of patients was 63 years, and the median duration of the disease was 24 months. Seventeen patients received Sbv, while nine patients were treated with liposomal amphotericin B (AmB), and another nine patients were treated with fluconazole. Patients treated with AmB received a total median accumulated dose of 2550mg. The mean duration of azole use was 120 days, and the daily dose ranged from 450 to 900mg. At the three-month follow-up visit, the cure rate was 35%, 67%, and 22% for Sbv, AmB, and azole groups, respectively. At the six-month follow-up visit, the cure rates for Sbv, AmB, and azole groups were 71%, 78%, and 33%, respectively. CONCLUSIONS: There is a scarcity of effective ML treatment alternatives, and based on our observations, fluconazole is not a valid treatment option.
local.publisher.countryBrasil
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://www.scielo.br/j/rsbmt/a/HndLWXRjkj5BCt7DZtyZLVv/?lang=en#

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Mucosal leishmaniasis- the experience of a Brazilian referral center.pdf
Tamanho:
857.5 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG